Overview of treatment options for invasive fungal infections

Medical Mycology

Volumn 49, Issue 6, 2011, Pages 561-580

  Pound, Melanie W ^a,b   Townsend, Mary L ^a,c   Dimondi, Vincent ^a   Wilson, Dustin ^a,d   Drew, Richard H ^a,e,f  

^a CAMPBELL UNIVERSITY   (United States)

^b NEW HANOVER REGIONAL MEDICAL CENTER   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

^d Cape Fear Valley Health System   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Amphotericin; Azole antifungals; Echinocandins

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; CASPOFUNGIN; CORTICOSTEROID; CYCLOSPORIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; IBUPROFEN; ITRACONAZOLE; MICAFUNGIN; NIFEDIPINE; PARACETAMOL; POSACONAZOLE; RAPAMYCIN; TRIAZOLE; VORICONAZOLE;

ABDOMINAL DISCOMFORT; ALLERGY; ALLOGENEIC STEM CELL TRANSPLANTATION; ANAPHYLAXIS; ANEMIA; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; AREA UNDER THE CURVE; ASPERGILLOSIS; ASPERGILLUS; BACTERIAL ENDOCARDITIS; BLADDER IRRIGATION; BLASTOMYCOSIS; BONE MARROW SUPPRESSION; BRONCHOSPASM; CANDIDA; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDEMIA; CANDIDIASIS; CANDIDURIA; CHILL; CHROMOMYCOSIS; CLAVISPORA LUSITANIAE; COCCIDIOIDOMYCOSIS; COLOR VISION DEFECT; COUGHING; CREATININE BLOOD LEVEL; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS; CRYPTOCOCCUS NEOFORMANS; DIARRHEA; DNA SYNTHESIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSPNEA; ENDOPHTHALMITIS; ESOPHAGUS CANDIDIASIS; FEBRILE NEUTROPENIA; FEVER; FUNGICIDAL ACTIVITY; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HEMATOLOGIC DISEASE; HEMOLYSIS; HEMOLYTIC ANEMIA; HISTOPLASMOSIS; HUMAN; HYPERCHLOREMIA; HYPERTRANSAMINASEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; IN VITRO STUDY; INJECTION SITE PAIN; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; KIDNEY CALCIFICATION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY TUBULE ACIDOSIS; LEISHMANIASIS; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; LUNG ASPERGILLOSIS; MAXIMUM PLASMA CONCENTRATION; MENINGITIS; MENINGOENCEPHALITIS; MENTAL DISEASE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; MUCORMYCOSIS; MYELODYSPLASTIC SYNDROME; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OROPHARYNX CANDIDIASIS; PANCYTOPENIA; PHLEBITIS; PHOTOPHOBIA; QT PROLONGATION; RASH; REVIEW; RHODOTORULA; RIGOR; SIDE EFFECT; SKIN MANIFESTATION; SPOROTRICHOSIS; STOMACH PH; SURVIVAL; SYSTEMIC MYCOSIS; THROMBOCYTOPENIA; TREATMENT PLANNING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; UREMIA; URTICARIA; VISCERAL LEISHMANIASIS; VISUAL DISORDER; VOMITING; ZYGOMYCETES; ZYGOMYCOSIS;

ANTIFUNGAL AGENTS; CHEMOPREVENTION; HUMANS; MYCOSES;

ASPERGILLUS;

EID: 79960459815     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2011.560197     Document Type: Review

References (240)

1. Zilberberg MD, Shorr AF, Kollef MH. Secular trends in candidemia-related hospitalization in the United States, 2000-2005. Infect Control Hosp Epidemiol 2008; 29: 978-980.
2. Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48: 1695-1703.
3. Chaudhuri HK, Montag BJ, Heidelberger C. Studies on f uorinated pyrimidines. III. The metabolism of 5-f uorouracil-2-C14 and 5-f uoroorotic-2-C14 acid in vivo. Cancer Res 1958; 18: 318-328.
4. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 2010; 50: 291-322.
5. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-535.
6. Mauceri AA, Cullen SI, Vandevelde AG, Johnson JE, III. Flucytosine. An effective oral treatment for chromomycosis. Arch Dermatol 1974; 109: 873-876.
7. Polak A, Scholer HJ. Mode of action of 5-f uorocytosine and mechanisms of resistance. Chemotherapy 1975; 21: 113-130.
8. Waldorf AR, Polak A. Mechanisms of action of 5-f uorocytosine. Antimicrob Agents Chemother 1983; 23: 79-85.
9. Polak A. Mode of action of 5-f uorocytosine and 5-f uorouracil in dematiaceous fungi. Sabouraudia 1983; 21: 15-25. (Pubitemid 13127909)
10. Bicanic T, Wood R, Meintjes G, et al. High-dose amphotericin B with f ucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis 2008; 47: 123-130. (Pubitemid 351920599)
11. Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination anti-fungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004; 363: 1764-1767. (Pubitemid 38698379)
12. van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodef-ciency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997; 337: 15-21.
13. Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphot-ericin B alone and combined with f ucytosine in the treatment of cryp-toccal meningitis. N Engl J Med 1979; 301: 126-131. (Pubitemid 10225854)
14. Smego RA Jr, Perfect JR, Durack DT. Combined therapy with am-photericin B and 5-f uorocytosine for Candida meningitis. Rev Infect Dis 1984; 6: 791-801.
15. Struijk DG, Krediet RT, Boeschoten EW, Rietra PJ, Arisz L. Antifun-gal treatment of Candida peritonitis in continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 1987; 9: 66-70. (Pubitemid 17039822)
16. Cuenca-Estrella M. Combinations of antifungal agents in therapy-what value are they? J Antimicrob Chemother 2004; 54: 854-869. (Pubitemid 39529979)
17. Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination antifungal therapy. Antimicrob Agents Chemother 2004; 48: 693-715. (Pubitemid 38280314)
18. Bava AJ, Negroni R. Comparative study of six antifungal treatments in an experimental model of murine cryptococcosis. Eur J Epidemiol 1992; 8: 422-426.
19. Chen HH, Liushih RN, Hsieh WC. Combined in vitro activity of amphotericin B and 5-f uorocytosine against Cryptococcus neofor-mans and Candida albicans. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi 1982; 15: 106-112.
20. Hamilton JD, Elliott DM. Combined activity of amphotericin B and 5-f uorocytosine against Cryptococcus neoformansin vitro and in vivo in mice. J Infect Dis 1975; 131: 129-137.
21. Kujath P, Lerch K, Kochendorfer P, Boos C. Comparative study of the eff cacy of f uconazole versus amphotericin B/f ucytosine in surgical patients with systemic mycoses. Infection 1993; 21: 376-382.
22. Lewis RE, Diekema DJ, Messer SA, Pfaller MA, Klepser ME. Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J Antimicrob Chemother 2002; 49: 345-351. (Pubitemid 34162627)
23. Martin E, Maier F, Bhakdi S. Antagonistic effects of f uconazole and 5-f uorocytosine on candidacidal action of amphotericin B in human serum. Antimicrob Agents Chemother 1994; 38: 1331-1338. (Pubitemid 24170716)
24. Rabinovich S, Shaw BD, Bryant T, Donta ST. Effect of 5-f uorocytosine and amphotericin B on Candida albicans infection in mice. J Infect Dis 1974; 130: 28-31.
25. Andes D, van OM. In vivo characterization of the pharmacodynam-ics of flucytosine in a neutropenic murine disseminated candidiasis model. Antimicrob Agents Chemother 2000; 44: 938-942. (Pubitemid 30165273)
26. Turnidge JD, Gudmundsson S, Vogelman B, Craig WA. The postan-tibiotic effect of antifungal agents against common pathogenic yeasts. J Antimicrob Chemother 1994; 34: 83-92. (Pubitemid 24237596)
27. Polak A. 5-Fluorocytosine-current status with special references to mode of action and drug resistance. Contrib Microbiol Immunol 1977; 4: 158-167.
28. Hope WW, Tabernero L, Denning DW, Anderson MJ. Molecular mechanisms of primary resistance to f ucytosine in Candida albicans. Antimicrob Agents Chemother 2004; 48: 4377-4386. (Pubitemid 39434901)
29. Fasoli M, Kerridge D. Isolation and characterization of f uoropyrim-idine-resistant mutants in two Candida species. Ann N Y Acad Sci 1988; 544: 260-263. (Pubitemid 19259328)
30. Drew RH, Townsend M. Antifungal drug resistance: clinical relevance and impact of antifungal drug use. Curr Fungal Infect Rep 2010; 4: 129-136.
31. St-Germain G, Laverdiere M, Pelletier R, et al. Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: report on 453 cases between 2003 and 2005. Can J Infect Dis Med Microbiol 2008; 19: 55-62. (Pubitemid 351547673)
32. Messer SA, Moet GJ, Kirby JT, Jones RN. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007). J Clin Microbiol 2009; 47: 1942-1946.
33. Cutler RE, Blair AD, Kelly MR. Flucytosine kinetics in subjects with normal and impaired renal function. Clin Pharmacol Ther 1978; 24: 333-342. (Pubitemid 8396512)
34. Valeant Pharmaceuticals International. Flucytosine Package Insert. Valeant Pharmaceuticals International 2007 March 1. Accessed 16 July 2010 from the website: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id = 5117.
35. Polak A. Pharmacokinetics of amphotericin B and f ucytosine. Postgrad Med J 1979; 55: 667-670.
36. Dannaoui E, Abdul M, Arpin M, et al. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. Antimicrob Agents Chemother 2006; 50: 2464-2470. (Pubitemid 43993187)
37. Schonebeck J, Polak A, Fernex M, Scholer HJ. Pharmacokinetic studies on the oral antimycotic agent 5-f uorocytosine in individuals with normal and impaired kidney function. Chemotherapy 1973; 18: 321-336.
38. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of systemic antifungal drugs. Clin Pharmacokinet 1983; 8: 17-42. (Pubitemid 13174271)
39. Block ER, Bennett JE, Livoti LG, et al. Flucytosine and amphotericin B: hemodialysis effects on the plasma concentration and clearance. Studies in man. Ann Intern Med 1974; 80: 613-617.
40. Thompson GR III, Wiederhold NP, Fothergill AW, et al. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.Antimicrob Agents Chemother 2009; 53: 309-311.
41. Pfaller MA, Messer SA, Boyken L, et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 2005; 43: 2163-2167. (Pubitemid 40656221)
42. Clinical and Laboratory Standards Institute WP2. CLSI Reference Method for BrothDilution Antifungal Susceptibility Testing of Yeasts, document M27-A3, 3rd ed. Wayne, IN: CLSI, 2008.
43. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro activities of anidu-lafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to f uconazole. J Clin Microbiol 2005; 43: 5425-5427. (Pubitemid 41612308)
44. Benson JM, Nahata MC. Clinical use of systemic antifungal agents. Clin Pharm 1988; 7: 424-438.
45. Vermes A, van Der SH, Guchelaar HJ. Flucytosine: correlation between toxicity and pharmacokinetic parameters. Chemotherapy 2000; 46: 86-94. (Pubitemid 30093541)
46. Stamm AM, Diasio RB, Dismukes WE, et al. Toxicity of amphotericin B plus f ucytosine in 194 patients with cryptococcal meningitis. Am J Med 1987; 83: 236-242.
47. Meyer RD, Axelrod JL. Fatal aplastic anemia resulting from f ucyto-sine. JAMA 2010; 228: 1573.
48. Hiddemann W, Essink ME, Fegeler W, et al. Antifungal treatment by amphotericin B and 5-f uorocytosine delays the recovery of normal hematopoietic cells after intensive cytostatic therapy for acute myeloid leukemia. Cancer 1991; 68: 9-14.
49. Pasqualotto AC, Howard SJ, Moore CB, Denning DW. Flucytosine therapeutic monitoring: 15 years experience from the UK. J Antimi-crob Chemother 2007; 59: 791-793. (Pubitemid 47073421)
50. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphot-ericin B with f uconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992; 326: 83-89.
51. Ellis ME, Al-Abdely H, Sandridge A, Greer W, Ventura W. Fungal endocarditis: evidence in the world literature, 1965-1995. Clin Infect Dis 2001; 32: 50-62. (Pubitemid 32150950)
52. Schmid S, Martenet AC, Oelz O. Candida endophthalmitis: clinical presentation, treatment and outcome in 23 patients. Infection 1991; 19: 21-24.
53. Tiphine M, Letscher-Bru V, Herbrecht R. Amphotericin B and its new formulations: pharmacologic characteristics, clinical eff cacy, and tolerability. Transpl Infect Dis 1999; 1: 273-283.
54. Brajtburg J, Bolard J. Carrier effects on biological activity of amphot-ericin B. Clin Microbiol Rev 1996; 9: 512-531. (Pubitemid 26366536)
55. Vertut-Croquin A, Bolard J, Gary-Bobo CM. Transfer of amphoteri-cin B from gel state vesicles to mycoplasma cells: biphasic action on potassium transport and permeability. Antimicrob Agents Chemother 1985; 28: 167-171. (Pubitemid 15019942)
56. Three Rivers Pharmaceuticals. Amphotec Package Insert. Three Rivers Pharmaceuticals 2009 January 1. Accessed 15 July 2010 from the website: http://www.3riverspharma.com/docs/amphotec-pi.pdf.
57. X-Gen Pharmaceuticals. Amphotericin B deoxycholate Package Insert. X-Gen Pharmaceuticals 2009 January 1. Accessed 17 July 2010 from the website: http://www.xgen.us/Injectables/Amphotericin%20B/Amphotericin-f les/insert/Amphotericin-pi.pdf.
58. Brajtburg J, Elberg S, Schwartz DR, et al. Involvement of oxidative damage in erythrocyte lysis induced by amphotericin B. Antimicrob Agents Chemother 1985; 27: 172-176. (Pubitemid 15002425)
59. Surarit R, Shepherd MG. The effects of azole and polyene antifungals on the plasma membrane enzymes of Candida albicans. J Med Vet Mycol 1987; 25: 403-413. (Pubitemid 18028519)
60. Di BG, Spedicato I, Picciani C, D'Antonio D, Piccolomini R. In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies. Antimicrob Agents Chemother 2004; 48: 4453-4456. (Pubitemid 39434915)
61. Andes D, Stamsted T, Conklin R. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimi-crob Agents Chemother 2001; 45: 922-926. (Pubitemid 32182046)
62. Klepser ME, Wolfe EJ, Jones RN, Nightingale CH, Pfaller MA. Antifun-gal pharmacodynamic characteristics of f uconazole and amphoteri-cin B tested against Candida albicans. Antimicrob Agents Chemother 1997; 41: 1392-1395. (Pubitemid 27231450)
63. Vitale RG, Meis JF, Mouton JW, Verweij PE. Evaluation of the post-antifungal effect (PAFE) of amphotericin B and nystatin against 30 zygomycetes using two different media. J Antimicrob Chemother 2003; 52: 65-70. (Pubitemid 36850087)
64. Sokol-Anderson ML, Brajtburg J, Medoff G. Amphotericin B-induced oxidative damage and killing of Candida albicans. J Infect Dis 1986; 154: 76-83. (Pubitemid 16088305)
65. Young LY, Hull CM, Heitman J. Disruption of ergosterol biosynthesis confers resistance to amphotericin B in Candida lusitaniae. Antimi-crob Agents Chemother 2003; 47: 2717-2724. (Pubitemid 37040239)
66. Pfaller MA, Messer SA, Boyken L, et al. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS antifungal surveillance program conducted in 2001 and 2002. J Clin Microbiol 2004; 42: 3142-3146. (Pubitemid 38938071)
67. Pfaller MA, Messer SA, Hollis RJ. Strain delineation and antifungal susceptibilities of epidemiologically related and unrelated isolates of Candida lusitaniae. Diagn Microbiol Infect Dis 1994; 20: 127-133.
68. Robbie G, Wu TC, Chiou WL. Poor and unusually prolonged oral absorption of amphotericin B in rats. Pharm Res 1999; 16: 455-458. (Pubitemid 29162106)
69. Christiansen KJ, Bernard EM, Gold JW, Armstrong D. Distribution and activity of amphotericin B in humans. J Infect Dis 1985; 152: 1037-1043. (Pubitemid 16236694)
70. Moen MD, Lyseng-Williamson KA, Scott LJ. Liposomal amphoteri-cin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 2009; 69: 361-392.
71. Dler-Moore JP, Proffitt RT. Amphotericin B lipid preparations: what are the differences? Clin Microbiol Infect 2008; 14 (Suppl. 4): 25-36. (Pubitemid 351593914)
72. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: Clinical eff cacy and toxicities. Clin Infect Dis 1998; 27: 603-618. (Pubitemid 28422013)
73. Enzon Pharmaceuticals. Abelcet Package insert. Enzon Pharmaceuticals 2002. Accessed 16 November 2010 from the website: http://www.abelcet.com/
74. Astellas Pharma US. Ambisome Package Insert. Astellas 2005. Accessed 16 November 2010 from the website: http://www.astellas.us/docs/ambisome.pdf
75. Atkinson AJ Jr, Bennett JE. Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother 1978; 13: 271-276. (Pubitemid 8280992)
76. Barchiesi F, Arzeni D, Compagnucci P, et al. In vitro activity of five antifungal agents against clinical isolates of Saccharomyces cerevi-siae. Med Mycol 1998; 36: 437-440.
77. Tzatzarakis MN, Tsatsakis AM, Charvalos E, Vakalounakis D. Comparison of in vitro activities of amphotericin, clotrimazole, econazole, miconazole, and nystatin against Fusarium oxysporum. J Environ Sci Health B 2001; 36: 331-340. (Pubitemid 34137130)
78. Lewis RE, Wiederhold NP, Klepser ME. In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergil-lus, Fusarium, and Scedosporium spp. Antimicrob Agents Chemother 2005; 49: 945-951. (Pubitemid 40327708)
79. Kantarcioglu AS, Yucel A. In-vitro activities of terbinaf ne, itraconazole and amphotericin B against Aspergillus and Cladosporium species. J Chemother 2002; 14: 562-527.
80. Lacroix C, de Chauvin MF. In vitro activity of amphotericin B, itraconazole, voriconazole, posaconazole, caspofungin and terbinafine against Scytalidium dimidiatum and Scytalidium hyalinum clinical isolates. J Antimicrob Chemother 2008; 61: 835-837. (Pubitemid 351426067)
81. Walsh TJ, Melcher GP, Rinaldi MG, et al.Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol 1990; 28: 1616-1622. (Pubitemid 20212896)
82. Blum G, Perkhofer S, Haas H, et al. Potential basis for amphotericin B resistance in Aspergillus terreus. Antimicrob Agents Chemother 2008; 52: 1553-1555. (Pubitemid 351522034)
83. Espinel-Ingroff A, Johnson E, Hockey H, Troke P. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies. J Antimicrob Chemother 2008; 61: 616-620. (Pubitemid 351321136)
84. Torres-Narbona M, Guinea J, Martinez-Alarcon J, Pelaez T, Bouza E. In vitro activities of amphotericin B, caspofungin, itracon-azole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. Antimicrob Agents Chemother 2007; 51: 1126-1129. (Pubitemid 46355313)
85. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12: 308-329.
86. Goodwin SD, Cleary JD, Walawander CA, Taylor JW, Grasela TH Jr. Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infect Dis 1995; 20: 755-761.
87. Paterson DL, David K, Mrsic M, et al. Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHO-TEC: data from the Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) registry. J Antimicrob Chemother 2008; 62: 1392-1400.
88. Gales MA, Gales BJ. Rapid infusion of amphotericin B in dextrose. Ann Pharmacother 1995; 29: 523-529.
89. Llanos A, Cieza J, Bernardo J, et al. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int 1991; 40: 302-308.
90. Nicholl TA, Nimmo CR, Shepherd JD, Phillips P, Jewesson PJ. Amphotericin B infusion-related toxicity: comparison of two-and four-hour infusions. Ann Pharmacother 1995; 29: 1081-1087.
91. Janknegt R, de MS, Bakker-Woudenberg IA, Crommelin DJ. Liposomal and lipid formulations of amphotericin B. Clinical phar-macokinetics. Clin Pharmacokinet 1992; 23: 279-291.
92. Herbrecht R. Safety of amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis 1997; 16: 74-80. (Pubitemid 27095988)
93. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764-771. (Pubitemid 29114295)
94. Lister J. Amphotericin B Lipid Complex (Abelcet) in the treatment of invasive mycoses: the North American experience. Eur J Haematol Suppl 1996; 57: 18-23.
95. Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphoteri-cin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000; 31: 1155-1163. (Pubitemid 32295443)
96. Herbrecht R, Letscher V, Andres E, Cavalier A. Safety and eff cacy of amphotericin B colloidal dispersion. An overview. Chemotherapy 1999; 45 (Suppl. 1): 67-76. (Pubitemid 29308663)
97. Gurwith M, Mamelok R, Pietrelli L, Du MC. Renal sparing by am-photericin B colloidal dispersion: clinical experience in 572 patients. Chemotherapy 1999; 45 (Suppl. 1): 39-47. (Pubitemid 29308660)
98. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillo-sis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-360. (Pubitemid 351265310)
99. Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 1801-1812.
100. Kauffman CA, Bustamante B, Chapman SW, Pappas PG. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45: 1255-1265. (Pubitemid 351411897)
101. Nussbaum ES, Hall WA. Rhinocerebral mucormycosis: changing patterns of disease. Surg Neurol 1994; 41: 152-156. (Pubitemid 24158876)
102. Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis. Clin Infect Dis 2005; 41: 1217-1223. (Pubitemid 41532662)
103. Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45: 807-825. (Pubitemid 47580372)
104. Dismukes WE, Cloud G, Gallis HA, et al. Treatment of crypto-coccal meningitis with combination amphotericin B and f ucytosine for four as compared with six weeks. N Engl J Med 1987; 371: 334-341. (Pubitemid 17118707)
105. Dromer F, Bernede-Bauduin C, Guillemot D, Lortholary O. Major role for amphotericin B-f ucytosine combination in severe crypto-coccosis. PLoS One 2008; 3: e2870.
106. Sharkey PK, Graybill JR, Johnson ES, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of crypto-coccal meningitis in patients with AIDS. Clin Infect Dis 1996; 22: 315-321. (Pubitemid 26056161)
107. Baddour LM, Perfect JR, Ostrosky-Zeichner L. Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. Clin Infect Dis 2005; 40 (Suppl. 6): S409-413. (Pubitemid 40563298)
108. Coker RJ, Viviani M, Gazzard BG, et al. Treatment of cryptococco-sis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS 1993; 7: 829-835. (Pubitemid 23212449)
109. Hamill RJ, Sobel JD, El-Sadr W, et al. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxy-cholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of eff cacy and safety. Clin Infect Dis 2010; 51: 225-232.
110. Shoham S, Cover C, Donegan N, Fulnecky E, Kumar P. Crypto-coccus neoformans meningitis at 2 hospitals in Washington, D.C.: adherence of health care providers to published practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2005; 40: 477-479. (Pubitemid 40216519)
111. Anaissie EJ, Darouiche RO, bi-Said D, et al. Management of invasive candidal infections: results of a prospective, randomized, multi-center study of f uconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996; 23: 964-972. (Pubitemid 26367478)
112. Phillips P, Shafran S, Garber G, et al. Multicenter randomized trial of f uconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 1997; 16: 337-345. (Pubitemid 27271820)
113. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing f uconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994; 331: 1325-1330. (Pubitemid 24347001)
114. Gafter-Gvili A, Vidal L, Goldberg E, Leibovici L, Paul M. Treatment of invasive candidal infections: systematic review and meta-analysis. Mayo Clin Proc 2008; 83: 1011-1021.
115. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415. (Pubitemid 34851833)
116. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus lipo-somal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-1402.
117. Ellis M, Bernsen R, li-Zadeh H, et al. A safety and feasibility study comparing an intermittent high dose with a daily standard dose of liposomal amphotericin B for persistent neutropenic fever. J Med Microbiol 2009; 58: 1474-1485.
118. Johnson PC, Wheat LJ, Cloud GA, et al. Safety and eff cacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 2002; 137: 105-109. (Pubitemid 34779154)
119. Petit N, Parola P, Dhiver C, Gastaut JA. Eff cacy and tolerance of am-photericin B in a lipid emulsion in the treatment of visceral leishma-niasis in AIDS patients. J Antimicrob Chemother 1996; 38: 154-157.
120. Moore EM, Lockwood DN. Treatment of visceral leishmaniasis. J Glob Infect Dis 2010; 2: 151-158.
121. Parker JD, Doto IL, Tosh FE. A decade of experience with blasto-mycosis and its treatment with amphotericin B. A National Communicable Disease Center Cooperative Mycoses Study. Am Rev Respir Dis 1969; 99: 895-902.
122. Bradsher RW. Histoplasmosis and blastomycosis. Clin Infect Dis 1996; 22 (Suppl. 2): S102-111. (Pubitemid 26256440)
123. Reichenspurner H, Gamberg P, Nitschke M, et al. Signif cant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc 1997; 29: 627-628. (Pubitemid 27123555)
124. Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillo-sis during prolonged neutropenia: A randomized, placebo-controlled trial. Clin Infect Dis 2008; 46: 1401-1408. (Pubitemid 351589940)
125. Monforte V, Roman A, Gavalda J. Nebulized amphotercin B prophylaxis for Aspergillus infection in lung transplantation: Study of risk factors. J Heart Lung Transplant 2001; 20: 1274-1281. (Pubitemid 34017312)
126. Schwartz S, Behre G, Heinemann V, et al. Aerosolized amphoteri-cin B inhalations as prophylaxis of invasive Aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 1999; 93: 3654-3661. (Pubitemid 29249811)
127. Palmer SM, Perfect JR, Howell DN, et al. Candidal anastomotic infection in lung transplant recipients: successful treatment with a combination of systemic and inhaled antifungal agents. J Heart Lung Transplant 1998; 17: 1029-1033. (Pubitemid 28499035)
128. Laoudi Y, Paolini JB, Grimfed A, Just J. Nebulised corticosteroid and amphotericin B: an alternative treatment for ABPA? Eur Respir J 2008; 31: 908-909.
129. Purcell IF, Corris PA. Use of nebulised liposomal amphotericin B in the treatment of Aspergillus fumigatus empyema. Thorax 1995; 50: 1321-1323.
130. Castagnola E, Moresco L, Cappelli B, et al. Nebulized liposomal amphotericin B and combined systemic antifungal therapy for the treatment of severe pulmonary aspergillosis after allogeneic hematopoietic stem cell transplant for a fatal mitochondrial disorder. J Chemother 2007; 19: 339-342. (Pubitemid 47075132)
131. Arthur R, Drew RH, Perfect J. Novel modes of antifungal drug administration. Expert Opin Investig Drugs 2004; 13: 903-932. (Pubitemid 39117682)
132. Conneally E, Cafferkey MT, Daly PA, Keane CT, McCann SR. Nebulized amphotericin B as prophylaxis against invasive aspergil-losis in granulocytopenic patients. Bone Marrow Transplant 1990; 5: 403-406. (Pubitemid 20344122)
133. De Laurenzi A, Matteocci A, Lanti A, et al. Amphotericin B prophylaxis against invasive fungal infections in neutropenic patients: a single center experience from 1980 to 1995. Infection 1996; 24: 361-366. (Pubitemid 26356500)
134. Calvo V, Borro JM, Morales P, et al. Antifungal prophylaxis during the early postoperative period of lung transplantation. Valencia Lung Transplant Group. Chest 1999; 115: 1301-1304. (Pubitemid 29230637)
135. Casey P, Garrett J, Eaton T. Allergic bronchopulmonary aspergillosis in a lung transplant patient successfully treated with nebulized amphotericin. J Heart Lung Transplant 2002; 21: 1237-1241. (Pubitemid 35300473)
136. Fan-Havard P, O'Donovan C, Smith SM, et al. Oral f uconazole versus amphotericin B bladder irrigation for treatment of candidal funguria. Clin Infect Dis 1995; 21: 960-965.
137. Leu HS, Huang CT. Clearance of funguria with short-course anti-fungal regimens: a prospective, randomized, controlled study. Clin Infect Dis 1995; 20: 1152-1157.
138. Jacobs LG, Skidmore EA, Freeman K, Lipschultz D, Fox N. Oral fluconazole compared with bladder irrigation with amphotericin B for treatment of fungal urinary tract infections in elderly patients. Clin Infect Dis 1996; 22: 30-35. (Pubitemid 26022008)
139. Hsu CC, Chang RH. Two-day continuous bladder irrigation with amphotericin B. Clin Infect Dis 1995; 20: 1570-1571.
140. Wise GJ, Kozinn PJ, Goldberg P. Amphotericin B as a urologic irrig-ant in the management of noninvasive candiduria. J Urol 1982; 128: 82-84. (Pubitemid 12048767)
141. Trinh T, Simonian J, Vigil S, Chin D, Bidair M. Continuous versus intermittent bladder irrigation of amphotericin B for the treatment of candiduria. J Urol 1995; 154: 2032-2034.
142. Gnau T. Amphotericin B dosage for bladder irrigation. Am J Hosp Pharm 1992; 49: 2705-2706.
143. Murray L, Reed J (eds.) Red Book, 2010 Edn. Montvale, NJ: Thomson Reuters (Healthcare Inc.), 2010.
144. Fera MT, La CE, De SA. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Expert Rev Anti Infect Ther 2009; 7: 981-998.
145. Chapman SW, Sullivan DC, Cleary JD. In search of the holy grail of antifungal therapy. Trans Am Clin Climatol Assoc 2008; 119: 197-215.
146. Wilson DT, Drew RH, Perfect JR. Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update. Mycopathologia 2009; 168: 313-327.
147. Mohr J, Johnson M, Cooper T, Lewis JS, Ostrosky-Zeichner L. Current options in antifungal pharmacotherapy. Pharmacotherapy 2008; 28: 614-645. (Pubitemid 351620030)
148. Thompson GR, III, Lewis JS. Pharmacology and clinical use of vori-conazole. Expert Opin Drug Metab Toxicol 2010; 6: 83-94.
149. Dodds-Ashley E, Lewis R, Lewis J, Martin C, Andes D. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006; 43: S28-39. (Pubitemid 44078894)
150. Pfizer. Diflucan (fluconazole) Package Insert. Pfizer Inc. 2010. Accessed 2 August 2010 from the website: http://www.pfizer.com/files/productsuspi- difucan-pdf-2010
151. Janssen-Ortho Inc. Sporanox (itraconazole capsules) Package Insert. Janssen-Ortho Inc. 2010. Accessed 2 August 2010 from the website: http://www.janssen-ortho.com/JOI/pdf-files/SporanoxCaps-Epdf2010
152. Dodds-Ashley E. Management of drug and food interactions with azole antifungal agents in transplant recipients. Pharmacotherapy 2010; 30: 842-854.
153. Janssen-Ortho Inc. Sporanox (itraconazole oral solution) Package Insert. Janssen-Ortho Inc. 2010. Accessed 2 August 2010 from the website: http://www.janssen-ortho.com/JOI/pdf-files/SporanoxOral-Epdf2010
154. Pfizer. Vfend (voriconazole) Package Insert. Pfizer Inc. 2010. Accessed 2 August 2010 from the website: http://www.pfizer.com/files/productsuspi-vfend pdf 2010
155. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36: 630-637. (Pubitemid 36259570)
156. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posa-conazole in healthy adults. Br J Clin Pharmacol 2004; 57: 218-222. (Pubitemid 38223535)
157. Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharma-cokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009; 53: 958-966.
158. Ezzet F, Wexler D, Courtney R, et al. Oral bioavailability of posacon-azole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005; 44: 211-220. (Pubitemid 40188942)
159. Lipp HP. Antifungal agents-clinical pharmacokinetics and drug interactions. Mycoses 2008; 51 (Suppl. 1): 7-18.
160. Schering Plough. Noxaf l (posaconazole) Package Insert. Schering Plough 2009. Accessed 2 August 2010 from the website: http://www.spfiles.com/pinoxaf l.pdf.2009
161. Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to f u-conazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010; 48: 1366-1377.
162. Cronin S, Chandrasekar PH. Safety of triazole antifungal drugs in patients with cancer. J Antimicrob Chemother 2010; 65: 410-416.
163. Goodwin ML, Drew RH. Antifungal serum concentration monitoring: an update. J Antimicrob Chemother 2008; 61: 17-25.
164. Bruggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009; 48: 1441-1458.
165. Barbaro G, Barbarini G, Calderon W, et al. Fluconazole versus itracon-azole for candida esophagitis in acquired immunodef ciency syndrome. Candida esophagitis. Gastroenterology 1996; 111: 1169-1177. (Pubitemid 26362240)
166. de WN, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with f uconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004; 39: 842-849. (Pubitemid 39244300)
167. Laine L, Dretler RH, Conteas CN, et al. Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS. A randomized trial. Ann Intern Med 1992; 117: 655-660.
168. Villanueva A, Gotuzzo E, Arathoon EG, et al. A randomized double-blind study of caspofungin versus f uconazole for the treatment of esophageal candidiasis. Am J Med 2002; 113: 294-299. (Pubitemid 35287295)
169. Krause DS, Simjee AE, van RC, et al. A randomized, double-blind trial of anidulafungin versus f uconazole for the treatment of esopha-geal candidiasis. Clin Infect Dis 2004; 39: 770-775. (Pubitemid 39244288)
170. Wilcox CM, Darouiche RO, Laine L, et al. A randomized, double-blind comparison of itraconazole oral solution and f uconazole tablets in the treatment of esophageal candidiasis. J Infect Dis 1997; 176: 227-232. (Pubitemid 27272873)
171. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus f ucon-azole for invasive candidiasis. N Engl J Med 2007; 356: 2472-2482. (Pubitemid 46919773)
172. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of f uconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845-851.
173. Slavin MA, Osborne B, Adams R, et al. Eff cacy and safety of f uconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545-1552.
174. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus f uconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407-1416. (Pubitemid 39518200)
175. Larsen RA, Bozzette SA, Jones BE, et al. Fluconazole combined with f ucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994; 19: 741-745. (Pubitemid 24301152)
176. Milefchik E, Leal MA, Haubrich R, et al. Fluconazole alone or combined with f ucytosine for the treatment of AIDS-associated cryptococcal meningitis. Med Mycol 2008; 46: 393-395. (Pubitemid 351552497)
177. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: prevention and treatment of cancer related infections. Accessed August 2, 2010 from the website: http://www.oralcancer-foundation.org/treatment/pdf/ infections-NCCN.pdf2009
178. Hostetler JS, Denning DW, Stevens DA. US experience with itracon-azole in Aspergillus, Cryptococcus and Histoplasma infections in the immunocompromised host. Chemotherapy 1992; 38 (Suppl. 1): 12-22.
179. Glasmacher A, Cornely O, Ullmann AJ, et al. An open-label randomized trial comparing itraconazole oral solution with f uconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother 2006; 57: 317-325. (Pubitemid 43160176)
180. Glasmacher A, Prentice A, Gorschluter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003; 21: 4615-4626. (Pubitemid 46594036)
181. Ally R, Schurmann D, Kreisel W, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and f uconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001; 33: 1447-1454. (Pubitemid 34246135)
182. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by f uconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366: 1435-1442. (Pubitemid 41483809)
183. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122-1131. (Pubitemid 36549632)
184. Lortholary O, Obenga G, Biswas P, et al. An international, retrospective analysis of 73 cases of invasive fusariosis treated with voricon-azole. Antimicrob Agents Chemother 2010;54: 4446-4450.
185. Siwek GT, Pfaller MA, Polgreen PM, et al. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagn Microbiol Infect Dis 2006; 55: 209-212. (Pubitemid 43928408)
186. Wingard JR, Carter SL, Walsh TJ, et al. Randomized double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection (IFI) after allo hematopoietic cell transplantation (HCT). Blood 2010; 116: 5111-5118.
187. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. f ucon-azole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-359. (Pubitemid 46148777)
188. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or flucon-azole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-347. (Pubitemid 46148776)
189. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergil-losis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44: 2-12. (Pubitemid 44968977)
190. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42: e61-65.
191. Micromedex [database on the Internet]. Micafungin. c2010. Accessed 16 November 2010 from the website: http://www.thomsonhc.com/hcs/librarian/ND-T/HCS/ ND-PR/Main/CS/20BED0/DUPLICATIONSHIELDSYNC/52CC97/ND-PG/PRIH/ND-B/HCS/SBK/2/ ND-P/Main/PFActionId/hcs.common.RetrieveDocumentCommon/DocId/2296/ContentSetId/ 31/SearchTerm/micafungin%20/SearchOption/BeginWith
192. Micromedex [database on the Internet]. Caspofungin. c2010. Accessed 16 November 2010 from the website: http://www.thomsonhc.com/hcs/librarian/ND-T/HCS/ ND-PR/Main/CS/7CD972/DUPLICATIONSHIELDSYNC/76ECAA/ND-PG/PRIH/ND-B/HCS/SBK/2/ ND-P/Main/PFActionId/hcs.common.RetrieveDocumentCommon/DocId/2516/ContentSetId/ 31/SearchTerm/caspofungin%20/SearchOption/BeginWith
193. Micromedex [database on the Internet]. Anidulafungin. c2010. Accessed 16 November 2010 from the website: http://www.thomsonhc.com/hcs/librarian/ND-T/HCS/ ND-PR/Main/CS/F1476A/DUPLICATIONSHIELDSYNC/B52CCA/ND-PG/PRIH/ND-B/HCS/SBK/2/ ND-P/MAIN/PFActionId/hcs.common.RetrieveDocumentCommon/DocId/2292/ContentSetId/ 31/SearchTerm/anidulafungin%20/SearchOption/BeginWith
194. Antachopoulos C, Meletiadis J, Sein T, Roilides E, Walsh TJ. Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species. Antimicrob Agents Chemother 2007; 51: 881-887. (Pubitemid 46355271)
195. Kurtz MB, Heath IB, Marrinan J, et al. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother 1994; 38: 1480-1489. (Pubitemid 24203556)
196. Nakai T, Uno J, Ikeda F, et al. In vitro antifungal activity of Mica-fungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. Antimicrob Agents Chemother 2003; 47: 1376-1381. (Pubitemid 36368600)
197. Astellas Pharma US I. Mycamine (micafungin) Package Insert. Astellas Pharma US Inc. 2008. Accessed 18 May 2010 from the website: http://www.astellas. us/docs/mycamine.pdf2010
198. Merck & Co. I. Cancidas (caspofungin) Package Insert. Merck & Co. Inc. 2010. Accessed 18 May 2010 from the website: http://www.merckcom/product/ usa/pi-circulars/c/cancidas/cancidas-pi pdf 2010
199. Pfizer Inc. Eraxis (anidulafungin) Package Insert. Pfizer Inc. 2010. Accessed 18 May 2010 from the website: http://media.Pfizer.com/files/products/ uspi-eraxis.pdf2010
200. Andes D, Diekema DJ, Pfaller MA, et al. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother 2010; 54: 2497-2506.
201. Forrest GN, Weekes E, Johnson JK. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect 2008; 56: 126-129.
202. Kabbara N, Lacroix C, Peffault de LR, et al. Breakthrough C. parap-silosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy. Haematologica 2008; 93: 639-640. (Pubitemid 351536400)
203. Clinical Laboratory and Standards Institute WP2. CLSI Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi: Approved Standard, document M38-A2, 2nd ed. Wayne, IN: Clinical Laboratory and Standards Institute, 2008.
204. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol 2008; 46: 2620-2629.
205. Quindos G, Eraso E. In vitro antifungal activity of anidulafungin. Rev Iberoam Micol 2008; 25: 83-91. (Pubitemid 351798335)
206. Quindos G, Eraso E, Javier Carrillo-Munoz A, Canton E, Peman J. In vitro antifungal activity of micafungin. Rev Iberoam Micol 2009; 26: 35-41.
207. Maligie MA, Selitrennikoff CP. Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins. Antimicrob Agents Chemother 2005; 49: 2851-2856. (Pubitemid 40917602)
208. Uchida K, Nishiyama Y, Yokota N, Yamaguchi H. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens. J Antibiot (Tokyo) 2000; 53: 1175-1181.
209. Sucher AJ, Chahine EB, Balcer HE. Echinocandins: the newest class of antifungals. Ann Pharmacother 2009; 43: 1647-1657.
210. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-1151. (Pubitemid 37222342)
211. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic f lamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36: 2950-2956. (Pubitemid 28429420)
212. Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopep-tide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000; 44: 57-62. (Pubitemid 30010672)
213. Zhanel GG, Karlowsky JA, Harding GA, et al. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob Agents Chemother 1997; 41: 863-865. (Pubitemid 27150550)
214. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002; 46: 245-247. (Pubitemid 34031636)
215. Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharma-cotherapy 2007; 27: 369-388. (Pubitemid 46327905)
216. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspo-fungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-2029. (Pubitemid 35461658)
217. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspo-fungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45: 883-893. (Pubitemid 47580382)
218. Betts RF, Nucci M, Talwar D, et al. A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009; 48: 1676-1684.
219. Colombo AL, Perfect J, DiNubile M, et al. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 2003; 22: 470-474. (Pubitemid 37100593)
220. DiNubile MJ, Strohmaier KM, Lupinacci RJ, et al. Eff cacy and safety of caspofungin therapy in elderly patients with proven or suspected invasive fungal infections. Eur J Clin Microbiol Infect Dis 2008; 27: 663-670.
221. Arathoon EG, Gotuzzo E, Noriega LM, et al. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 2002; 46: 451-457. (Pubitemid 34087195)
222. DiNubile MJ, Lupinacci RJ, Berman RS, Sable CA. Response and relapse rates of candidal esophagitis in HIV-infected patients treated with caspofungin. AIDS Res Hum Retroviruses 2002; 18: 903-908.
223. Villanueva A, Arathoon EG, Gotuzzo E, et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001; 33: 1529-1535. (Pubitemid 34246147)
224. Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncom-parative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006; 107: 2888-2897. (Pubitemid 44937044)
225. Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81: 320-326. (Pubitemid 43255714)
226. Caillot D, Thiebaut A, Herbrecht R, et al. Liposomal amphoteri-cin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 2007; 110: 2740-2746. (Pubitemid 350250344)
227. Maertens J, Raad I, Petrikkos G, et al. Eff cacy and safety of caspo-fungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-1571. (Pubitemid 39578526)
228. Mattiuzzi GN, Alvarado G, Giles FJ, et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 2006; 50: 143-147. (Pubitemid 43042914)
229. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus lipo-somal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369: 1519-1527. (Pubitemid 46670281)
230. Dupont BF, Lortholary O, Ostrosky-Zeichner L, Stucker F, Yeldandi V. Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. Crit Care 2009; 13: R159.
231. de Wet NT, Bester AJ, Viljoen JJ, et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. f uconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 2005; 21: 899-907. (Pubitemid 40477250)
232. Pettengell K, Mynhardt J, Kluyts T, et al. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol Ther 2004; 20: 475-481. (Pubitemid 39120260)
233. Hiramatsu Y, Maeda Y, Fujii N, et al. Use of micafungin versus f uconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation. Int J Hematol 2008; 88: 588-595.
234. Krause DS, Reinhardt J, Vazquez JA, et al. Phase 2, randomized, dose-ranging study evaluating the safety and eff cacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemoth-er 2004; 48: 2021-2024. (Pubitemid 38691592)
235. Zaoutis TE, Jafri HS, Huang LM, et al. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics 2009; 123: 877-884.
236. Benjamin DK, Jr., Smith PB, Arrieta A, et al. Safety and pharma-cokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther 2010; 87: 93-99.
237. Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006; 25: 1110-1115. (Pubitemid 44900673)
238. Queiroz-Telles F, Berezin E, Leverger G, et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive can-didiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 2008; 27: 820-826.
239. Benjamin DK, Jr., Driscoll T, Seibel NL, et al. Safety and pharma-cokinetics of intravenous anidulafungin in children with neutrope-nia at high risk for invasive fungal infections. Antimicrob Agents Chemother 2006; 50: 632-638. (Pubitemid 43190976)
240. Brielmaier BD, Casabar E, Kurtzeborn CM, McKinnon PS, Ritchie DJ. Early clinical experience with anidulafungin at a large tertiary care medical center. Pharmacotherapy 2008; 28: 64-73.